alt
alt
alt
United States

Browse Cardiology

 

Cardiology

MYNX CONTROL™ Vascular Closure Device

The innovative design and predictable deployment of MYNX CONTROL™ Vascular Closure Device delivers outstanding performance and control, for consistently secure arterial closures.

Product Description

MYNX CONTROL™ Vascular Closure Device (VCD) integrates dual-mode active sealing and resorbability with a next-generation delivery system to maximize predictability, safety, and ease of use.

Clinical Resources

Documentation

Clinical Articles

Mynx Vascular Closure Device Achieves Reliable Closure and Hemostasis of Percutaneous Transfemoral Venous Access in a Porcine Vascular Model
S. Sanjay Srivatsa, MBBChir1; Arjun Srivatsa1; Taylor A. Spangler, DVM, DACVP2. The Journal of Invasive Cardiology. February 2015

The MYNXGRIP™ Vascular Closure Device
Hoang Minh Thai, MD, FACC, FSCAI, and Barry S. Weinstock, MD. Endovascular Today. April 2012.

Successful Reduction of Surgeries Secondary to Arterial Access Site Complications
A Retrospective Review at a Single-Center with an Extravascular Closure Device.
Noor S, Meyers S, Curl R. Vascular and Endovascular Surgery. May 2010;44(5):345-9.

A Prospective Randomized Single-blind trial of Patient Comfort Following Vessel Closure
Extravascular Synthetic Sealant Closure Provides Less Pain than a Self-tightening Suture Vascular Compression Device.
Fargen KM, Hoh BL, Mocco J. J Neurointerv Surg. 2011;3(3):219-23

Mynx Vascular Closure Device Early Ambulation Study
Vikranth R. Gongidi, DO; Ahsan Jafir, DO; and Vijay Verma, MD, FACC, FSCAI. Endovascular Today. October 2013

Occurrence of angiographic femoral artery complications after vascular closure with Mynx and AngioSeal
Fargen KM, Velat GJ, Lawson MF, et al. Journal of Neurolnterventional Surgery. 2013;5(2):161-4

Use of Vascular Closure Device After Access of Common Femoral Artery Through an Existing Stent
George JC. Vascular Disease Management. 2012;9(5):E68-E70.

Two Years of Extravascular Closure With the Mynx™ Vascular Closure Device
The Baptist Memorial Hospital experience revisited.
David Wolford, MD, FACC. Endovascular Today. August 2010.

Mynx Closure in a Patient Treated for Chronic Total Occlusion of the Iliac Artery with Multiple Sheath Exchanges.
A Case Review. Michael S. Fenster, MD. TCTMD. May 2009.

Why Extravascular Closure?
The Baptist Memorial Hospital Experience with the Mynx Vascular Closure Device
David Wolford, MD, FACC. Endovascular Today. August 2009.

The Safety and Efficacy of an Extravascular, Water-Soluble Sealant for Vascular Closure
Initial Clinical Results for Mynx. D. Scheinert MD et al. Catheterization and Cardiovascular Interventions. November 2007.

Ordering Information

In the United States, email us your order at GMB-CORDIS-CUSTOMER-SUPPORT@cardinalhealth.com or call us at 800.327.7714. Outside of the United States, contact your local MYNX™ device distributor.

The MYNX CONTROL™ VCD includes:

  • (1) MYNX CONTROL™ VCD including balloon catheter and integrated polyethylene glycol sealant
  • (1) 10 ml locking syringe 
Product Size Order Number
MYNX CONTROL™ VCD 5F MX5060
MYNX CONTROL™ VCD 6F / 7F MX6760

IFU

INDICATIONS FOR USE: MYNX CONTROL™ VCD is indicated for use to seal femoral arterial access sites while reducing times to hemostasis and
ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F, or 7F procedural sheath.

PRECAUTIONS: MYNX CONTROL™ VCD should only be used by a trained licensed physician or healthcare professional. MYNX CONTROL™ VCD should
not be used in patients with a known allergy to PEG. MYNX CONTROL™ VCD should not be used with sheaths longer than 12 cm effective length or
incompatible sheaths listed in Table 9 of the Instructions for Use.

WARNINGS: Do not use if components or packaging appear to be damaged or defective or if any portion of the packaging has been previously
opened. DO NOT REUSE OR RESTERILIZE. MYNX CONTROL™ VCD is for single use only. The catheter is loaded with a single hydrogel sealant. Reuse
of the device would result in no delivery of hydrogel sealant. Do not use MYNX CONTROL™ VCD if the puncture site is located above the most inferior
border of the inferior epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks, since such a puncture site may result in
a retroperitoneal hematoma/bleed. Perform a femoral angiogram to verify the location of the puncture site. Do not use MYNX CONTROL™ VCD if the
puncture is through the posterior wall or if there are multiple punctures, as such punctures may result in a retroperitoneal hematoma/bleed.

CAUTION: Federal (US) law restricts this device to sale by or on the order of a physician.

IMPORTANT INFORMATION: Prior to use, refer to the Instructions for Use supplied with this device for indications, contraindications, side effects,
suggested procedure, warnings, and precautions.

See IFU for complete information.